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Mitophagy specifically recognizes and removes damaged or superfluous mitochondria
to maintain mitochondrial homeostasis and proper neuronal function. Defective
mitophagy and the resulting accumulation of damaged mitochondria occur in several
neurodegenerative diseases. Previously, we showed mitochondrial dysfunction in
astrocytes with POLG mutations, and here, we examined how POLG mutations affect
mitophagy in astrocytes and how this can be ameliorated pharmacologically. Using
induced pluripotent stem cell (iPSC)-derived astrocytes carrying POLG mutations, we
found downregulation of mitophagy/autophagy-related genes using RNA sequencing-
based KEGG metabolic pathway analysis. We confirmed a deficit in mitochondrial
autophagosome formation under exogenous stress conditions and downregulation of
the mitophagy receptor p62, reduced lipidation of LC3B-II, and decreased expression
of lysosome protein lysosomal-associated membrane protein 2A (LAMP2A). These
changes were regulated by the PINK1/Parkin pathway and AKT/mTOR/AMPK/ULK1
signaling pathways. Importantly, we found that double treatment with nicotinamide
riboside (NR) and metformin rescued mitophagy defects and mitochondrial dysfunction
in POLG-mutant astrocytes. Our findings reveal that impaired mitophagy is involved
in the observed mitochondrial dysfunction caused by POLG mutations in astrocytes,
potentially contributing to the phenotype in POLG-related diseases. This study also
demonstrates the therapeutic potential of NR and metformin in these incurable
mitochondrial diseases.
Keywords: mitophagy, astrocytes, POLG, IPSC (induced pluripotent stem cells), nicotinamide riboside (NR),
metformin, mitochondria
Frontiers in Cell and Developmental Biology | www.frontiersin.org 1 September 2021 | Volume 9 | Article 737304
fcell-09-737304 September 20, 2021 Time: 13:1 # 2
Chen et al. Mitophagy Dysfunction in POLG-Astrocytes
GRAPHICAL ABSTRACT | Hypothetical mechanisms of mitophagy dysfunction in POLG-mutant astrocytes.
INTRODUCTION
Mitochondrial DNA (mtDNA) polymerase γ (pol γ) replicates
the mitochondrial genome and the holoenzyme consists of
a catalytic subunit (encoded by POLG) and a dimeric form
of its accessory subunit (encoded by POLG2) (Graziewicz
et al., 2006). Mutations in POLG are associated with a wide
range of mitochondrial diseases that form a continuum from
catastrophic early-onset hepato-cerebral degeneration to late-
onset progressive external ophthalmoplegia (Hikmat et al., 2020).
Mitochondria are fundamental, subcellular organelles with
multiple functions including ATP generation and participating
in the regulation of cell metabolism, calcium (Ca2+) signaling,
redox state, neurotransmission, and plasticity (Lin and Beal,
2006; Mattson et al., 2008; Sheng and Cai, 2012; Fang
et al., 2016; Kerr et al., 2017). Mutations in POLG lead to
neuronal loss conditioned by abnormal mtDNA homeostasis
comprising both depletion and a time-dependent increase in
mtDNA damage, along with loss of complex I (Tzoulis et al.,
2014). We have demonstrated that these findings could be
replicated using induced pluripotent stem cell (iPSC)-derived
neural stem cells (NSCs) in which we also found evidence of
increased reactive oxygen species (ROS) production and cellular
senescence (Liang et al., 2020b). In iPSC-derived neurons, we
also showed mitochondrial dysfunction and mtDNA depletion in
dopaminergic neurons from POLG patients (Liang et al., 2021).
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FIGURE 1 | Generation and characterization of patient-specific astrocytes carrying POLG mutations. (A) Schematic of dual differentiation and seeding paradigm for
astrocytes (upper panel), representative phase-contrast images (middle panel) and immunostaining for specific stages during neural induction from iPSCs to
astrocytes (lower panel). (B,C) Representative phase-contrast images and confocal images of immunostaining for GFAP (red), S100β (green), EAAT-1 (red), and GS
(green). Nuclei are stained with DAPI (blue). Scale bar is 50 µm. (D) Flow cytometric analysis for percentage of the positive cells expressing GFAP, S100β, CD44,
EAAT-1, and GS. (E) Clustering heat map [log (value + 1)] for DEGs in HNA and control iPSC-derived astrocytes. (F) mRNA expression of astrocyte, neuron, and
oligodendrocyte-related genes in HNA and all iPSC-derived astrocytes. The different markers are listed on the x-axis, and mRNA expression is on the y-axis. Results
are expressed as fragments per kilobase million (FPKM). Data information: The data in B–D represent one clone from AG05836 control. The data in E represent
HNA, four different control astrocytes with three clones from Detroit 551 control and one clone from AG05836 control. The data in F represent HNA, four different
control astrocytes with three clones from Detroit 551 control and one clone from AG05836 control, three clones from WS5A and two clones from CP2A.
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Mitochondria are dynamic organelles, and mitochondrial
fusion and fission are essential processes for maintaining
homeostasis via the segregation of damaged mitochondria
(Burté et al., 2015). Fusion and fission are also essential for
mitophagy, the selective autophagy pathway that recognizes
and degrades damaged or superfluous mitochondria (Youle
and Narendra, 2011; Fivenson et al., 2017; Lautrup et al., 2019).
Accumulating empirical evidence suggests that mitophagy
impairment contributes to neurodegenerative diseases such
as Alzheimer’s disease (AD) and Parkinson’s disease (PD)
(Kerr et al., 2017; Fang et al., 2019b). Several mitophagy
pathways are recognized including the PINK1/Parkin pathway
(Vives-Bauza et al., 2010; Deas et al., 2011) and the energy-
sensitive PI3K/AKT/mTOR/ULK1 axis (Egan et al., 2011;
Hung et al., 2021). The kinase mammalian target of rapamycin
(mTOR) is a major negative regulator of mitophagy/autophagy
(Heras-Sandoval et al., 2014), and AMP-activated protein
kinase (AMPK) is recognized as an important mitophagy
activator, acting through a pleiotropic mechanism involving
mTOR inhibition and direct phosphorylation/activation
of Unc-51-like kinase 1 (ULK1) (Kim et al., 2011; Hung
et al., 2021). The mTOR is a downstream target of both
phosphatidylinositol 3 kinase (PI3K), and AKT and is
activated by receptors of both neurotrophic and growth
factors, promoting cell growth, differentiation, and survival
(Manning and Toker, 2017).
Astrocytes are the major glial cell type in the central
nervous system and serve multiple functions including synaptic
signaling, neurotransmitter synthesis and recycling, as well as
nutrient uptake and regulation of local blood flow (Haydon
and Carmignoto, 2006). Many of these processes depend on
local metabolism and/or energy utilization. Astrocytes respond
to increases in neuronal activity and metabolic demand by
upregulating glycolysis, but also possess a significant capacity
for mitochondrial energy metabolism (Jackson and Robinson,
2018). Growing evidence also links astrocyte dysfunction with
neurodegenerative disease (Acosta et al., 2017; Liddelow et al.,
2017; Richetin et al., 2020; Sonninen et al., 2020). While
astrocytic mitophagy/autophagy plays a fundamental role in
maintaining brain function and health, disease-driven astrocytic
mitophagy/autophagy impairment can potentiate inflammation,
oxidative stress, and neural death (Maldonado et al., 2018;
Wang and Xu, 2020).
A previous study in mice links mitochondrial dysfunction in
astrocytes with POLG-related disease (Ignatenko et al., 2018). In
an earlier study, we showed that POLG-mutant astrocytes
exhibited mitochondrial dysfunction including loss of
mitochondrial membrane potential, loss of ATP production,
loss of complex I, disturbed NAD+/NADH metabolism, and
mtDNA depletion (Liang et al., 2020a). However, whether and
how POLG mutations affect mitophagy in these cells remains
unclear. In this study, we aimed to identify how mitochondrial
dysfunction driven by POLG mutations impacts mitophagy. We
used astrocytes derived from iPSCs of two POLG patients, one
homozygous for c.2243G > C; p.W748S and one compound
heterozygous for c.1399G > A/c.2243G > C; p.A467T/W748S
mutations. We identified a defect in mitophagy with lowered
lysosomal activity and abnormal regulation of multiple pathways
including PINK1/Parkin and AKT/mTOR/AMPK/ULK1.
More importantly, treatment with nicotinamide riboside
(NR) and metformin rescued the impaired mitophagy via
upregulating the SIRT1/AMPK pathway and downregulating
the mTOR pathway, which further improved mitochondrial
function. Our results show, for the first time, that POLG




The project was approved by the Western Norway Committee for
Ethics in Health Research (REK nr. 2012/919).
Generation of Induced Pluripotent Stem
Cells, Neural Stem Cells, and Astrocyte
Differentiation
The fibroblasts from one homozygous c.2243G > C,
p.W748S/W748S (WS5A) and one compound heterozygous
c.1399G > A/c.2243G > C, p.A467T/W748S (CP2A) patient
were collected by punch biopsy. Detroit 551 fibroblasts
(ATCC R© CCL 110TM) and AG05836B fibroblasts (RRID:
CVCL_2B58) were used as control lines. The generation and
maintenance of iPSCs and their derived NSCs were described
previously (Liang et al., 2020a,b, 2021). Astrocytes were
differentiated from NSCs according to the protocol described
previously (Liang et al., 2020a). In addition, commercial human
normal astrocytes (HNA) (Lonza) was applied as a control.
Details of the samples used in this study are described in
Supplementary Table 1.
Nicotinamide Riboside and Metformin
Treatment
Nicotinamide riboside was provided by Evandro Fei Fang
(University of Oslo, Norway). The cells were seeded in six-
well plates and treated with metformin (Sigma-Aldrich, St.
Louis, MO, United States) and/or NR for 72 h. The medium
was changed daily.
Immunofluorescence Staining
Cells were fixed with 4% (v/v) paraformaldehyde (PFA) and
blocked using blocking buffer containing 10% (v/v) normal goat
serum (Sigma-Aldrich) with 0.3% (v/v) TritonTM X-100 (Sigma-
Aldrich). The cells were then incubated with primary antibody
solution overnight at 4◦C and further stained with secondary
antibody solution (1:800 in blocking buffer) for 1 h at room
temperature (RT). The coverslips were mounted onto cover slides
using ProLongTM diamond antifade mounting medium with
DAPI (Invitrogen, Carlsbad, CA, United States). The detailed
information of the antibodies used is provided in Supplementary
Tables 2, 3.
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FIGURE 2 | (Continued)
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FIGURE 2 | Transcriptomic analysis shows downregulation of mitophagy/autophagy in POLG-mutant astrocytes. (A) Clustering heap map [log (value + 1)] for DEGs
in WS5A, CP2A, and control astrocytes. (B) Venn diagram of the DEGs in two compared groups of WS5A astrocytes vs. controls and CP2A astrocytes vs. controls.
(C,D) KEGG metabolic pathway analysis for DEGs in two compared groups of WS5A astrocytes vs. controls (C) and CP2A astrocytes vs. controls (D).
(E) Unsupervised clustering of DEGs in mitophagy/autophagy pathways in WS5A astrocytes vs. controls and CP2A astrocytes vs. controls. (F) Differential analysis of
mitophagy-related genes in patient astrocytes compared to controls. (G) KEGG pathway enrichment analysis of the mitophagy-related genes in patient astrocytes
compared to controls. (H) KEGG module enrichment analysis of the mitophagy-related genes in patient astrocytes compared to controls. (I–L) RNA-seq analysis for
the mRNA expression of mitophagy-related genes MAP1LC3B (I), SQS1M1 (J), PINK1 (K), and PRKN (L) in WS5A, CP2A, and control astrocytes. Results are
expressed as FPKM. Data information: The data in I–L represent four different control astrocytes, including three clones from Detroit 551 control and one clone from
AG05836 control, three clones from WS5A and two clones from CP2A. Data are presented as mean ± SEM for the number of samples (n ≥ 3 per clone).
Mann–Whitney U test was used for the data presented in I–L. Significance is denoted for p-values of less than 0.05. *p < 0.05; ***p < 0.001.
Live Cell Staining for Mitochondrial
Morphology
Cells were seeded on µ-Slide 4 Well (Ibidi) and cultured at 37◦C
in a humidified incubator overnight. The cells were stained with
500 nM MitoTracker Green (MTG) (Invitrogen) for 45 min at
37◦C. Images were captured using the Leica TCS SP8 confocal
microscope (Leica Microsystems).
Mitochondrial Volume and Membrane
Potential Measurement
Cells were stained with 150 nM MitoTracker Deep Red (MTDR)
(Invitrogen) and 150 nM MTG (Invitrogen) for 45 min.
Cells treated with 100 µM FCCP (Abcam, Cambridge, MA,
United States) were used as negative control. Stained cells were
detached with TrypLETM express (Invitrogen) and analyzed on
a FACS BD AccuriTM C6 flow cytometer (BD Biosciences, San
Jose, CA, United States). The data analysis was performed using
the AccuriTM C6 software (BD Biosciences).
Mitophagy Detection Assay
Astrocytes were seeded on µ-Slide 4 Well and cultured at
37◦C overnight. The cells were then treated with 10 µg/mL
FCCP for 24 h and were co-stained with mitophagy dye
and lysosome dye using a Mitophagy Detection Kit (Dojindo)
according to the instruction. MTDR was used to label the
mitochondria. Images were captured using the Leica TCS SP8
confocal microscope (Leica Microsystems, Wetzlar, Germany).
Quantitative measurements of immunofluorescence images were
performed with Image J software (Image J 1.52a; Wayne Rasband
National Institutes of Health, United States1). More than five
areas were randomly chosen for quantitative evaluations.
Mitochondrial Complex I Enzyme Activity
Assay
We used the Complex I Enzyme Activity Microplate Assay Kit
(Abcam: ab109721) to measure complex I activity. All steps were
performed according to the manufacturer’s protocol. Cells were
seeded in six-well plates at a density of 200,000 cells per well
before the initiation of the experiment. Six hours after seeding,
cells were treated with different concentrations of metformin
for 72 h and then harvested. Extracted samples were loaded
into a 96-well microplate and incubated for 3 h before washing
three times with buffer. Assay solution was added, and the
reaction was measured using a microplate reader (INFINITE
1https://imagej.nih.gov/ij
F50) with a wavelength of 450 nm for 90 min. Activity is
expressed as the change in absorbance per minute (mOD/min)
per 130 µg of cell lysate.
Western Blotting
Extraction of protein was performed using 1× RIPA extraction
buffer (Thermo Fisher Scientific, Carlsbad, CA, United States)
supplemented with protease inhibitor cocktail and phosphatase
inhibitor cocktail (Thermo Fisher Scientific). Protein
concentration was determined using PierceTM BCA Protein
Assay Kit (Thermo Fisher Scientific). The cell protein was loaded
into NuPAGETM 4–12% Bis-Tris Protein Gels (Invitrogen)
and resolved in the PVDF membrane (BioRad, Hercules, CA,
United States) using the Trans-Blot R© TurboTM transfer system
(BioRad). Membranes were blocked with 5% non-fat dry milk
or 5% bovine serum albumin (BSA) in TBST for 1 h at RT.
Membranes were then incubated overnight at 4◦C with primary
antibodies. After washing in TBST three times, membranes were
incubated with donkey anti-mouse antibody or swine anti-rabbit
antibody conjugated to horseradish peroxidase secondary
for 1 h at RT. Super Signal West Pico Chemiluminescent
Substrate Kit (Thermo Fisher Scientific) was used as enzyme-
substrate according to the manufacturer’s recommendations.
The membranes were visualized by ChemiDoc imaging systems
(BioRad). Further details of the used antibodies are provided in
Supplementary Tables 2, 3.
RNA Sequencing
Total RNA was extracted using QIAGEN RNeasy Kit (QIAGEN,
Hilden, Germany). Library preparation was conducted at BGI
following the guide of the standard protocol. Library preparation
(BGISEQ-500RS High-throughput sequencing kit, PE50, V3.0,
MGI Tech Co., Ltd., Shenzhen, China), hybridization, and
sequencing were performed according to the manufacturer’s
procedure from BGI (BGI-Shenzhen, China). The sequencing
was performed at BGI-Shenzhen using the BGISEQ-500 system.
The sequencing data were filtered to remove very low-quality
reads using SOAP nuke (v1.5.2) software. The processed FASTQ
files were mapped to the human transcriptome and genome
using HISAT2 (v2.0.4). The genome version was GRCh38, with
annotations from Bowtie2 (v2.2.5). The expression level of the
gene was calculated by RSEM (v1.2.12). Differential expression
was done with DEseq2 (v1.4.5) package. To take an insight
into the change of phenotype, KEGG2 enrichment analysis of
annotated differentially expressed genes (DEGs) were performed
2https://www.kegg.jp
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FIGURE 3 | (Continued)
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FIGURE 3 | POLG-mutant astrocytes exhibit loss of mitochondrial volume and impaired mitochondrial function. (A–F) RNA-seq analysis for the mRNA expression of
fusion/fission-related genes DNM1L (A), FIS1 (B), MFF (C), MFN1 (D), MFN2 (E), and OPA1 (F) in WS5A, CP2A, and control astrocytes. Results are expressed as
FPKM. (G) Representative images of western blotting for MFN1, OPA1, p-DRP1 (Ser 616), DRP1, MFF, and GAPDH, and quantitative measurements of protein
levels of MFN1, OPA1, p-DRP1 (Ser 616), DRP1, and MFF in control and POLG-mutant astrocytes. (H) Representative images of live cell staining for MTG. The
upper panel scale bar is 50 µm; the lower panel is taken from the upper panel and the scale bar is 10 µm. (I,J) Flow cytometric measurements of total MTDR level
(I) and specific MTDR level normalized with MTG (J) in WS5A, CP2A, and control astrocytes. (K) Representative images of western blotting for TOMM20, PGC-1β,
GAPDH, and quantitative measurements of protein levels of TOMM20 and PGC-1β in control and POLG-mutant astrocytes. Data information: The data in A–F
represent four different control astrocytes, including three clones from Detroit 551 control and one clone from AG05836 control, three clones from WS5A and two
clones from CP2A. The data in G,K represent three different control astrocytes, including two clones from Detroit 551 control and one clone from AG05836 control,
three clones from WS5A and three clones from CP2A. The data in H represent one clone from AG05836 control, one clone from WS5A and one clone from CP2A.
The data in I,J represent three different control astrocytes, including two clones from Detroit 551 control and one clone from AG05836 control, three clones from
WS5A and three clones from CP2A. Data are presented as mean ± SEM for the number of samples (n ≥ 3 per clone). Mann–Whitney U test was used for the data
presented in A–K. Significance is denoted for p-values of less than 0.05. *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001; ns, not significant.
by Phyper3 based on hypergeometric test. Significant DEGs were
defined as ones with at least 0.3 fragments per kilobase million
(FPKM) level of expression in at least one of the conditions and a
q-value less than 0.05 by Bonferroni test.
Statistical Analyses
All data are expressed as mean± SEM for the number of samples
(n≥ 3). Statistical analyses were performed with GraphPad Prism
8.0.2 software (GraphPad Software) using the Mann–Whitney U
test. Significance is denoted for p-values of less than 0.05.
RESULTS
Generation and Characterization of
Patient-Specific Astrocytes Derived
From Induced Pluripotent Stem Cells
Carrying POLG Mutations
To generate astrocytes, we generated iPSCs showing
positive expression of SOX2, OCT4, and NANOG
(Supplementary Figure 1) and then differentiated these
into NSCs as described previously (Liang et al., 2020a,b, 2021).
Two patient lines were used, one homozygous for c.2243G > C;
p.W748S (WS5A) and the other a compound heterozygous
for c.1399G > A/c.2243G > C; p.A467T/W748S (CP2A).
We employed two control iPSC lines generated from normal
human fibroblast lines, Detroit 551 and AG05836B for wild-
type controls. In addition, one commercial human primary
astrocyte line, HNA, was used as a positive astrocyte lineage
control. We differentiated iPSC-derived NSCs to astrocytes as
previously described (Liang et al., 2020a,b, 2021). The astrocytes
from all patients and controls (Supplementary Figure 4)
showed typical stellate morphology (Figure 1A). To minimize
the intra-clonal phenotypic variability, multiple clones from
each individual patient were differentiated and included in
further studies.
Next, we characterized the iPSC-derived astrocytes using
immunostaining against key astrocyte markers. We found
robust expression of glial fibrillary acidic protein (GFAP)
and S100 calcium-binding protein β (S100β) (Figure 1B and
Supplementary Figure 2), and the functional markers excitatory
3https://en.wikipedia.org/wiki/Hypergeometric_distribution
amino acid transporter 1 (EAAT-1, also known as GLAST-1)
and glutamine synthetase (GS) (Figure 1C and Supplementary
Figure 3). Astrocytic identity and purity were confirmed using
flow cytometry against a panel of markers GFAP, S100β, CD44,
EAAT-1, and GS (Supplementary Figures 5–9). We found
that over 99% of cells were positive for all these markers
(Figure 1D). Additionally, we performed transcriptomic analysis
to characterize the specific cell type and the level of astrocyte
maturation from each individual clone. RNA sequencing (RNA-
seq) analysis was performed on three clones from WS5A,
two clones from CP2A, one clone from the commercial
HNA control, and four control astrocyte clones including one
clone from AG05836 and three clones from Detroit 551-
derived astrocytes.
Unsupervised hierarchical clustering showed that replicates
from the individual clones in the control group clustered
together, also clustering closely with HNA (Figure 1E). We
found significant homogeneity with a cluster of astrocytic
markers SOX9, NFIX, AQP4, ALDH1A1, GJA1, SLC1A3,
S100B, and GFAP in all the samples, but no expression
of neuronal markers NEROD1, NEUROG2, and RELN
and oligodendrocyte markers OLIG1, OLIG2, SOX10, and
NKX2.2 (Figure 1F).
Collectively, these data suggest that our protocol produces
nearly pure cultures of differentiated astrocytes that exhibit
similar transcriptional profiles to primary astrocytes.
Transcriptomic Analysis Shows
Downregulated Mitophagy/Autophagy
Genes in POLG-Mutant Astrocytes
We explored the DEGs as well as their related signaling and
metabolic pathways by comparing the transcriptomic profile
of patient (WS5A and CP2A) versus (vs.) control astrocytes.
Using unsupervised clustering, we identified a clear clustering
of the patient astrocytes (WS5A and CP2A) vs. controls
(Figure 2A). The Venn diagram showed 547 genes were
significantly differentially expressed in the WS5A lines and 509
in the CP2A lines compared to controls (statistical significance
cutoff was p = 0.05, Figure 2B).
KEGG metabolic pathway analysis revealed that the greatest
enrichment was for genes involved in the mitophagy/autophagy
pathways in both patient astrocyte lines (WS5A and
CP2A) compared to controls (Figures 2C,D). This was
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also significant for genes involved in PI3K/AKT signaling
pathway (Figures 2C,D). Unsupervised clustering of DEGs in
the mitophagy/autophagy pathways demonstrated a similar
pattern in WS5A cells vs. controls and CP2A cells vs. controls
(Figure 2E). Differential analysis showed the downregulation
of mitophagy genes in patient astrocytes compared to controls
(Figure 2F). In addition, KEGG pathway enrichment analyses
showed that there was also an associated dysregulation of both
oxidative phosphorylation (Figure 2G) and other metabolic
pathways, especially in NADH dehydrogenase-linked pathways
(Figure 2H) in patient astrocytes. We also demonstrated
significantly lower expressions of the mitophagy/autophagy-
related genes MAP1LC3B (Figure 2I), SQSTM1 (Figure 2J),
PINK1 (Figure 2K), and PRKN (Figure 2L) in both WS5A and
CP2A lines compared to controls. This evidence suggests linkage
between mitophagy changes and POLG-induced mitochondrial
dysfunction in these astrocytes.
Given that mitochondrial dynamics also plays a role in
mitochondrial quality control, we assessed transcript levels of
mitochondrial fusion/fission-related genes. Expression levels of
DNM1L, FIS1, MFF, MFN2, and OPA1 (Figures 3A–C,E,F)
were similar in both patient-derived and control astrocytes,
while expression of MFN1 was higher than control in WS5A
patient astrocytes (Figure 3D). When we measured protein levels
using western blotting, however, we found that levels of fusion
proteins mitofusin-1 (MFN1) and optic atrophy (OPA1), as
well as fission proteins mitochondrial fission factor (MFF) and
dynamin-related protein 1 (DRP1), were unaffected in patient
astrocytes (Figure 3G).
These results indicate that POLG mutations lead to changes
in astrocytes that appear to target the mitophagy/autophagy
pathways but not the mitochondrial fission/fusion pathways.
POLG-Mutant Astrocytes Exhibit Loss of
Mitochondrial Volume and Impaired
Mitochondrial Function
Next, we asked whether astrocytes generated from POLG
patients exhibited changes in mitochondrial volume and
function. We investigated mitochondrial morphology using
fluorescence microscopy, and biogenesis with western blotting
analysis, mitochondrial volume and mitochondrial membrane
potential with flow cytometry. We assessed mitochondrial
morphology using live cell staining with MTG and found
a similar mitochondrial morphology in both patients and
controls (Figure 3H).
We then investigated mitochondrial membrane potential.
To do this, we used flow cytometry and the combination
of the mitochondrial potential-dependent dye MTDR to
measure membrane potential and a mitochondrial potential-
independent dye MTG to assess mitochondrial volume.
We found significantly lower total MTDR (Figure 3I) and
specific MTDR when normalized to mitochondrial mass MTG
(Figure 3J) in both patient-derived astrocytes (WS5A and CP2A)
as compared to controls.
Next, we quantified mitochondrial proteins by western
blotting and observed decreased levels of TOMM20 in
both patient lines (WS5A and CP2A) compared to controls
(Figure 3K). To investigate if the decrease reflected
downregulated mitochondrial biogenesis, we assessed PGC-
1β, a positive regulator of mitochondrial biogenesis and
respiration. We observed a significant decrease in PGC-1β
in both patient-derived astrocytes (WS5A and CP2A) vs.
controls (Figure 3K).
These findings demonstrate that POLG mutations in
astrocytes are associated with loss of mitochondrial volume,
decreased mitochondrial membrane potential, and biogenesis.
POLG-Mutant Astrocytes Show Impaired
Mitophagy Regulation via PINK1/Parkin
Signaling Pathway
Evidence from RNA-seq analysis suggested downregulation of
mitophagy-related genes in patient iPSC-derived astrocytes. We
investigated this further by treating astrocytes with carbonyl
cyanide 4 – (trifluoromethoxy) phenylhydrazone (FCCP) – to
induce mitophagy and then evaluated mitophagosome formation
using a fluorescent mitophagy dye, together with a lysosome
dye and the mitochondrial dye MTDR. We observed decreased
red fluorescent puncta representing mitophagosome formation
and green fluorescent intensity for measuring lysosomes in both
patient and control astrocytes (Figure 4A). Quantification of
the mean fluorescence intensity in more than five random areas
showed that this decrease was significant for both mitophagy
(Figure 4B) and lysosome formation (Figure 4B) in patient
astrocytes. Consistent with the flow cytometric measurements
(Figures 3I,J), MTDR staining demonstrated a significantly
lower expression level in patient astrocytes as compared to
controls (Figure 4B). These data suggest that astrocytes with
POLG mutations lead to impaired mitophagy and decreased
lysosome formation.
Next, we examined mitophagy-related proteins including the
autophagosome marker microtubule-associated protein 1 light
chain 3β (LC3B), autophagy receptor p62, and lysosomal marker
lysosomal-associated membrane protein 2A (LAMP2A) using
western blotting. We found a decreased level of LC3B-II with a
significantly decreased ratio of LC3B-II/LC3B-I in both WS5A
and CP2A astrocytes compared to controls, indicating reduced
mitophagy in POLG-mutant astrocytes (Figure 4C). We also
identified the decreased protein expression of p62 (Figure 4C)
and downregulation of LAMP2A (Figure 4C) in POLG-mutant
astrocytes vs. control cells.
Loss mitochondrial membrane potential leads to activation
of PINK1, which stimulates the recruitment of Parkin to the
mitochondrial outer membrane of damaged mitochondria
and activates Parkin’s ubiquitin-ligase activity. Activated
mitochondrial Parkin leads to the ubiquitination of
mitochondrial proteins and subsequent mitophagy. We
investigated PINK1/Parkin pathway using western blotting and
found downregulation of PINK1 and Parkin in patient astrocytes
as compared to controls (Figure 4D), suggesting that POLG
mutations may impair mitochondrial priming of mitophagy in
astrocytes via PINK1/Parkin axis.
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FIGURE 4 | (Continued)
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FIGURE 4 | POLG-mutant astrocytes show impaired mitophagy regulation via PINK1/Parkin signaling pathway. (A) Representative confocal images of
immunostaining for mitophagy dye (red), lysosome dye (green), MTDR (purple), and MERGE (yellow) in WS5A, CP2A, and control astrocytes. Scale bar is 5 or 1 µm.
White arrows denote mitophagy formation. The cells were treated with FCCP for 24 h before staining. (B) Quantification of the immunofluorescence levels of
mitophagy dye, lysosome dye, and MTDR in WS5A, CP2A, and control astrocytes. (C) Representative images of western blotting for LAMP2A, p62, LC3B-I,
LC3B-II, and quantitative measurements of protein levels in WS5A, CP2A, and control astrocytes. (D) Representative images of western blotting for PINK1, Parkin
and quantitative measurements of protein levels of PINK1, Parkin in WS5A, CP2A, and control astrocytes. Data information: the data in A represent one clone from
Detroit 551 control, one clone from WS5A, and one clone from CP2A. The data in B, 40,000 astrocytes per sample were seeded and four different control
astrocytes, including three clones from Detroit 551 control and one clone from AG05836 control, two clones from WS5A, and two clones from CP2A were observed
with three technical replicates. The data in C,D represent three different control astrocytes, including two clones from Detroit 551 control and one clone from
AG05836 control, three clones from WS5A and three clones from CP2A. Data are presented as mean ± SEM for the number of samples (n ≥ 3 per clone).
Mann–Whitney U test was used for the data presented in B–D. Significance is calculated by comparison to controls and is denoted for p-values of less than 0.05.
*p < 0.05; **p < 0.01; ****p < 0.0001.
These findings suggest that POLG mutations can lead to
impaired mitophagy and decreased lysosome formation via
PINK1/Parkin-dependent pathway.
POLG-Mutant Astrocytes Demonstrate
Mitophagy Impairment via Modulating
AKT/mTOR/AMPK/ULK1 Signaling Axis
The mTOR signaling pathway plays a pivotal role in regulating
metabolism (Lazarou et al., 2015; Perluigi et al., 2015). Abnormal
activation of the AKT/mTOR/AMPK signaling pathway
inhibits autophagy, and defects affecting this pathway are
associated with human neurodegenerative disease (Saxton
and Sabatini, 2017). Therefore, we asked if abnormal
AKT/mTOR/AMPK signaling was driving the mitophagy
impairment in POLG-mutant astrocytes. To address this
question, we used western blotting to analyze p-mTOR, mTOR,
p-AKT, AKT, p-ULK1, ULK1, p-AMPK (T183 + T172), and
AMPK protein levels. We found a significantly increased ratio
of p-mTOR/mTOR in both patient astrocytes compared to
controls, indicating abnormal activation of the mTOR signaling
pathway (Figure 5A). We also demonstrated a significantly
increased ratio of p-AKT/AKT (Figure 5C) and a decrease
in the ratio of p-ULK1/ULK1 (Figure 5B) and p-AMPK
(T183 + T172)/AMPK (Figure 5D).
Taken together, these data indicate that POLG mutations
induced astrocytic mitophagy failure by regulating the
AKT/mTOR/AMPK/ULK1 signaling pathway.
Nicotinamide Riboside and Metformin
Treatment Rescue Mitophagy Defect by
Modulated SIRT1/AMPK/mTOR Pathway
in POLG-Mutant Astrocytes
Next, we asked whether the mitophagy defect could be
rescued (Figure 6A). The NAD+ precursor NR (Figure 6B)
potentially activates mitophagy/autophagy through the SIRT1
or mTOR pathways (Cea et al., 2012; Fang et al., 2017;
Vannini et al., 2019; Zheng et al., 2019). We therefore treated
WS5A astrocytes for 72 h with varying concentrations of
NR: 0, 0.25, 0.5, 1, and 2 mM. Cell viability was maintained
under all treatment conditions (Supplementary Figure 10).
Using western blotting, we found that cells treated with NR
alone showed upregulated phosphorylation of SIRT1/SIRT1
(p-SIRT1/SIRT1) ratio at all drug concentrations. We also
identified an increased p-AMPK (T183 + T172)/AMPK ratio,
but only in cells treated with 0.25 and 0.5 mM NR (Figure 6D).
No significant change in the mTOR pathway (Figure 6D) or the
mitophagy-related proteins LC3B-II/LC3B-I and p62 (Figure 6E)
were identified.
The AMPK activator metformin (Figure 6C) improves
mitophagy (Bhansali et al., 2020; Bharath et al., 2020; Kodali
et al., 2021) and mitochondrial function (Bharath et al., 2020)
via AMPK pathway activation. Therefore, we treated WS5A
astrocytes for 72 h with a series of metformin concentrations:
0, 1.25, 2.5, 5, and 10 mM. We observed that cell viability
was maintained under all treatment conditions (Supplementary
Figure 11). We found upregulated AMPK signaling with
increased phosphorylation of AMPK at T183 + T172/AMPK
ratio at all concentrations (Figure 6F). Metformin-treated
cells showed a dose-dependent decrease in phosphorylated
mTOR relative to total mTOR (Figure 6F) and an increased
LC3B-II/LC3B-I ratio, which peaked in cells treated with
2.5 mM, and increased p62 at all concentrations except
10 mM (Figure 6G).
We then examined whether combining NR and metformin
gave additional benefit. Cells were treated with the following
concentrations: 0 mM, NR 0.25 mM + metformin 1.25 mM, NR
0.5 mM + metformin 2.5 mM, NR 1 mM + metformin 5 mM,
and NR 2 mM + metformin 10 mM. Cell growth was maintained
under all treatment conditions (Supplementary Figure 12).
Combined treatment gave increased levels of p-SIRT1/SIRT1
ratio and p-AMPK (T183 + T172)/AMPK ratio, but decreased
level of p-mTOR/mTOR ratio at all concentrations (Figure 7A).
Dual treatment increased LC3B-II/LC3B-I ratio, showing a peak
in the cells treated with 0.5 mM NR and 2.5 mM metformin, while
10 mM did not reach significance (Figure 7B). The level of p62
increased at all concentrations (Figure 7B).
To confirm whether the dual treatment could rescue the
mitophagy, we treated both WS5A and CP2A astrocytes and
performed the mitophagy detection assay described above.
When incubated with FCCP for 24 h, we observed increased
mitophagy (higher red fluorescent signal) and lysosomal
formation (elevated green, fluorescent puncta) in the co-
treated patient cells as compared to controls (Figure 7C).
Quantification of the fluorescent signals showed significantly
increased levels for both mitophagy and lysosomal formation
(Figures 7D,E) in both patient iPSC-derived astrocytes
after the treatment.
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FIGURE 5 | POLG-mutant astrocytes demonstrate mitophagy impairment via modulating AKT/mTOR/AMPK/ULK1 signaling axis. (A) Representative images of
western blotting for p-mTOR, mTOR, GAPDH, and quantitative measurements of protein levels in WS5A, CP2A, and control astrocytes. (B) Representative images
of western blotting for p-ULK1, ULK1, GAPDH, and quantitative measurements of protein levels in WS5A, CP2A, and control astrocytes. (C) Representative images
of western blotting for p-AKT, AKT, GAPDH, and quantitative measurements of protein levels of in WS5A, CP2A, and control astrocytes. (D) Representative images
of western blotting for p-AMPK (T183 + T172), AMPK, GAPDH, and quantitative measurements of protein levels in WS5A, CP2A, and control astrocytes. Data
information: the loading controls from D are re-used from B,C. The data in A–D represent four different control astrocytes, including three clones from Detroit 551
control and one clone from AG05836 control, three clones from WS5A and three clones from CP2A. Data are presented as mean ± SEM for the number of samples
(n ≥ 3 per clone). Mann–Whitney U test was used for the data presented in A–D. Significance is denoted for p-values of less than 0.05. *p < 0.05; **p < 0.01;
***p < 0.001; ns, not significant.
Collectively, our data suggest NR alone and metformin alone
modulate mitophagy in POLG-mutant astrocytes in different
manners, while dual treatment of NR and metformin provides
a quantifiable improvement of the mitophagy impairment via
regulating SIRT1/AMPK/mTOR signaling pathway in POLG-
mutant astrocytes.
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FIGURE 6 | Nicotinamide riboside and metformin treatment modulated SIRT1/AMPK/mTOR pathway in POLG-mutant astrocytes. (A) Schematic diagram of
compound treatment for POLG-mutant astrocytes. (B,C) Chemical structure of NR (B) and metformin (C). (D) Representative images and quantification of western
blotting for p-SIRT1, SIRT-1, p-AMPK (T183 + T172), AMPK, p-mTOR, mTOR, and GAPDH in the POLG WS5A astrocytes treated with a serial concentration of NR
alone for 72 h. (E) Representative images and quantification of the western blotting for LC3B-I, LC3B-II, p62, and GAPDH in the POLG WS5A astrocytes treated
with a serial concentration of NR alone for 72 h. (F) Representative images and quantification of western blotting for p-SIRT1, SIRT1, p-AMPK (T183 + T172),
AMPK, p-mTOR, mTOR, and GAPDH in the POLG WS5A astrocytes treated with a serial concentration of metformin alone for 72 h. (G) Representative images and
quantification of the western blotting for LC3B-I, LC3B-II, p62, and GAPDH in the POLG WS5A astrocytes treated with a serial concentration of metformin alone for
72 h. Data information: the data in D–G represent one clone from WS5A. Mann–Whitney U test was used for the data presented in D–G. Significance is calculated
by comparison to non-treated cells and is denoted for p-values of less than 0.05. *p < 0.05; **p < 0.01; ***p < 0.001; ns, not significant.
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FIGURE 7 | Nicotinamide riboside and metformin co-treatment rescue mitophagy defect in POLG-mutant astrocytes. (A) Representative images and quantification
of western blotting for p-SIRT1, SIRT1, p-AMPK (T183 + T172), AMPK, p-mTOR, mTOR, GAPDH, and in the POLG WS5A astrocytes treated with a serial
concentration of NR and metformin co-treatment for 72 h. (B) Representative images and quantification of the western blotting for LC3B-I, LC3B-II, p62, and
GAPDH in the POLG WS5A astrocytes treated with a serial concentration of NR and metformin co-treatment for 72 h. (C) Representative confocal images of
immunostaining for mitophagy dye (red), lysosome dye (green), and MERGE (yellow) in WS5A and CP2A astrocytes with and without NR and metformin dual
treatment. Scale bar is 5 or 1 µm. White arrows denote mitophagy formation. (D,E) Quantification of the puncta numbers/cell of mitophagy dye, lysosome dye, and
MERGE in WS5A (D) and CP2A astrocytes (E) with and without NR and metformin co-treatment. Data information: the data in A,B represent one clone from WS5A.
The data in C represent one clone from WS5A with and without co-treatment, one clone from CP2A with and without co-treatment. The data in D,E, 40,000
astrocytes per sample were seeded and two clones from WS5A with and without co-treatment and two clones from CP2A with and without co-treatment were
observed with three technical replicates. Mann–Whitney U test was used for the data presented in A,B,D,E. Significance is calculated by comparison to non-treated
cells and is denoted for p-values of less than 0.05. *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001; ns, not significant.
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Nicotinamide Riboside and Metformin
Treatment Improve Mitochondrial
Function in POLG-Mutant Astrocytes
Metformin is a known inhibitor of respiratory chain complex
I, but this has been shown to be concentration dependent
(Owen et al., 2000). There is convincing evidence that
inhibition of complex I occurs only at higher metformin
concentrations, while at lower concentrations, it improves
mitochondrial respiratory chain function (Wang et al.,
2019). To check the effect of our treatment, we treated
cells with NR, metformin, or both using the following
concentrations: 0 mM, NR 0.25 mM + metformin 1.25 mM, NR
0.5 mM + metformin 2.5 mM, NR 1 mM + metformin 5 mM,
and NR 2 mM + metformin 10 mM and measured the complex
I subunit NDUFB10 expression using western blotting. We
observed increased complex I expression with metformin alone
or co-treatment when this drug was used at lower concentrations
(Figures 8A,C,D). In addition, we found increased complex I
enzyme activity in cells treated with metformin 1.25 mM, but
not with other concentrations (Supplementary Figure 13). To
investigate whether NR and metformin treatment could improve
the mitochondrial biogenesis in POLG-mutant astrocytes, we
then examined PGC-1α expression using western blotting and
found that PGC-1α also tended to increase in patient astrocytes
under all treatment conditions, but only at the concentration of
the NR 0.5 mM + metformin 2.5 mM and NR 1 mM + metformin
5 mM with significant statistical significance (Figures 8A–D).
Next, we checked the effect of treatment on cell growth,
mitochondrial mass, and membrane potential. We treated
astrocytes with 0.5 mM NR and 2.5 mM metformin, the
concentrations demonstrating the most significant effect as
defined in earlier assays. We found that combined treatment did
lead to an increase in cell number (Figures 8E,F), mitochondrial
mass (Figure 8G), and mitochondrial membrane potential;
both total (Figure 8H) and specific levels normalized to mass
(Figure 8I) although the increase was small.
Taken together, these data indicate that NR and metformin
treatment improved the mitochondrial biogenesis and functions
in POLG-mutant astrocytes, suggesting the mitophagy enhancers
as potential treatments for POLG-related disorders.
DISCUSSION
POLG mutations impair the replication of mtDNA and cause a
range of mitochondrial diseases many of which affect the brain
(Hikmat et al., 2020). We showed it was possible to replicate the
cellular phenotypes of mitochondrial dysfunction and abnormal
NAD+ metabolism in neural cells (Liang et al., 2020b, 2021)
and confirmed these changes in iPSC-derived astrocytes (Liang
et al., 2020a). Guided by unsupervised transcriptomic analysis,
which indicated a major dysregulation of mitophagy/autophagy,
we found that POLG mutations were clearly associated with
impaired mitophagy in astrocytes. This impairment occurs
via multiple mechanisms including (a) downregulation of
the autophagic/mitophagic protein p62 and reduced lipidation
of LC3B-II, (b) impaired autophagosome–lysosome fusion,
(c) downregulation of the PINK1/Parkin pathway, and (d)
dysregulation of AKT/mTOR/AMPK/ULK1 pathway. Further
and most notably, we demonstrate that NR and metformin
treatment improved the impaired mitophagy machinery and
appeared to restore the mitochondrial defect. This opens new
possibilities for the treatment of these disorders by using
mitophagy-enhancing reagents.
In our study, we chose healthy, age-matched control iPSCs and
patient-specific iPSCs then differentiated them into astrocytes
using a modified technique (Liang et al., 2020a,b, 2021). We are
fully aware that the current state of the art for iPSC studies is
to use gene-corrected isogenic controls; however, the presence
of compound mutations, such as those used in this study
(CP2A mutation), makes the generation of individual controls
impracticable. At the same time, it has been stated that the high
efficiency of genome cutting and repair makes the introduction
of heterozygous alleles by the standard CRISPR/Cas9 technique
near impossible (EauClaire and Webb, 2019; Liang et al., 2020a,b,
2021).
We performed RNA-seq analysis to confirm the cellular
identity and screen for changes in cellular pathways affected
by the presence of POLG mutations in astrocytes (Liang
et al., 2020a). We found that both patient and control
astrocytes showed similar astrocytic lineage profiles. Pathway
analysis showed clear dysregulation of genes involved
in mitophagy/autophagy, with both patient lines being
downregulated. This was confirmed by assessing the individual
genes involved in mitophagy/autophagy. We identified multiple
downregulated genes in several mitophagy/autophagy-related
pathways including the PI3K/AKT signaling pathway and
cAMP signaling pathway as well as metabolic pathways. While
mitochondrial fusion and fission are important activities for
the removal of defective organelles via mitophagy, we observed
similar transcriptomic profiles in patient and control astrocytes.
Our data therefore suggest that while POLG mutations lead to
the downregulation of mitophagy/autophagy-related genes, this
appears to be independent of mitochondrial fission/fusion.
To investigate how dysregulated mitophagy might impact
POLG affected mitochondria, we looked at changes in
mitochondrial function including mitochondrial volume,
membrane potential, and biogenesis. We found that POLG-
mutant astrocytes had reduced mitochondrial volume, lower
membrane potential, and decreased mitochondrial biogenesis
factor PGC-1β. This suggests that POLG not only disrupts
mitophagy regulation but might also impair mitochondrial
biogenesis. Thus, our study suggests that mitochondrial
biogenesis and mitophagy are coordinated to regulate
mitochondrial homeostasis and maintain cellular energy
levels in tissues such as the brain.
Consistent with the transcriptomic findings, we observed
that mitophagy activity was diminished under FCCP-induced
conditions in both patient cell lines. When we measured the
LC3 conversion (LC3B-I–LC3B-II) by western blot analysis,
the steady-state levels of LC3B-II were significantly lower in
both patient lines. There was also a lower expression of p62.
Autophagic adapter protein p62 is the substrate of Parkin
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FIGURE 8 | Nicotinamide riboside and metformin treatment improve mitochondrial function in POLG-mutant astrocytes. (A) Representative images of the western
blotting for NDUFB10, PGC-1α, and GAPDH in the POLG WS5A astrocytes treated with a serial concentration of NR alone, metformin alone, and co-treatment for
72 h. (B–D) Protein quantifications of the western blotting in A for NDUFB10 and PGC-1α in the POLG WS5A astrocytes treated with a serial concentration of NR
alone (B), metformin alone (C), and co-treatment (D) for 72 h. (E) Representative phase-contrast images of WS5A astrocytes before and after the dual treatment of
NR 0.5 mM and metformin 2.5 mM. Scale bar is 50 µm. (F) Cell number counting of WS5A astrocytes before and after the dual treatment of NR 0.5 mM and
metformin 2.5 mM. (G–I) Flow cytometric analysis for MTG (G) and MMP at total level measured by TMRE (H) and specific MMP level calculated by total TMRE/MTG
(I) of WS5A astrocytes before and after the dual treatment of NR 0.5 mM and metformin 2.5 mM. MTG, MMP, and specific MMP were normalized with non-treated
cells. (J) Summary of the possible disease mechanisms in astrocyte defects and neuronal loss in POLG-related disorders. Data information: the data in A–I represent
one clone from WS5A. Mann–Whitney U test was used for the data presented in B–D and F–I. Significance is calculated by comparison to non-treated cells and is
denoted for p-values of less than 0.05. *p < 0.05; **p < 0.01; ***p < 0.001; ns, not significant.
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and is required for Parkin-induced mitophagy (Song et al.,
2016). Thus, aberrant p62 could influence the balance of
mitophagy and further disturb mitochondrial quality control.
Accumulation of misfolded proteins is known to induce
aberrant p62 expression, and p62 is involved in multiple
pathways associated with neurodegeneration (Homma et al.,
2014; Ma et al., 2019). Abnormal expression of p62 can
induce mitophagy and autophagy dysfunction, which can further
accelerate misfolded protein aggregation. Based on our study,
the data suggest that p62 is associated with POLG-related
diseases and impaired Parkin-mediated mitophagy. To dissect
what was driving the impairment of mitophagy, we examined
the molecular signaling pathways involved. We showed that
POLG mutations impaired mitochondrial priming of mitophagy
via the PINK1/Parkin pathway. In mammalian cells, lower
mitochondrial membrane potential leads to accumulation of
PINK1 on the outer mitochondrial membrane (OMM) and
subsequent recruitment of the E3 ubiquitin ligase Parkin.
Parkin-mediated ubiquitination of OMM proteins serves as
a general signal recognized by autophagy adaptor proteins,
such as p62, which further target LC3B and ubiquitin
chains, translocating these dysfunctional mitochondria into
phagophores. We previously demonstrated the downregulation
of the PINK1/Parkin pathway and showed that POLG mutations
drive a lower level of ATP in astrocytes (Liang et al., 2020a). Given
that ATP is a key regulator of PINK1-mediated mitophagy by
controlling PINK1 translation levels (Lee et al., 2015), we suggest
that POLG-induced ATP depletion downregulates the translation
of PINK1 and therefore the recruitment of Parkin in response to
mitochondrial depolarization.
We also detected reduced lysosome formation in POLG-
mutant astrocytes following FCCP treatment and a reduction
in the protein level of lysosome-related membrane protein
LAMP2A, indicating damage or dysfunction of lysosomes.
Damaged mitochondria are degraded by the autophagy-
lysosome pathway (Plotegher and Duchen, 2017), and studies
in PARK2-PD fibroblasts suggest that lysosomal function may
be influenced by mitochondrial quality control (Guerra et al.,
2019). Our data suggest that mutations in POLG induce
mitochondrial dysfunction that leads to lysosomal impairment
and impairment of mitophagosome-lysosome fusion. Lysosomal
impairment, in turn, can trigger mitophagy failure and functional
mitochondrial defects in astrocytes. In addition, LAMP2A
mediates lysosome fusion and is essential for the final stage of
mitophagy. A recent study showed the LAMP2A is required
for the clearance of mitochondria but is dispensable for
PINK1/Parkin-mediated mitophagy (Liu et al., 2020). We thus
conclude that POLG mutations may impair the mitophagy
machinery in astrocytes in both a PINK1/Parkin-dependent and
independent manner, which includes impairment of autophagy-
lysosome pathway.
Our previous studies showed that POLG-mutant astrocytes
generated less ATP and significantly higher levels of lactate
than controls indicating a shift from OXPHOS to glycolysis
(Liang et al., 2020a). Given that AMPK is a key metabolic
sensor/regulator and essential to balance glycolysis and
mitochondrial metabolism in order to control cellular
stress and survival (Kishton et al., 2016), we speculated
that this metabolic shift could inhibit the AMPK signaling
pathway. This, in turn, would modulate mTOR signaling
via its upstream activator AKT and the downstream ULK1
signaling leading to downregulation of the mitophagy
machinery. To investigate how the AMPK, mTOR, and
PI3K/AKT pathway might impact POLG-affected mitophagy,
we investigated changes in phosphorylated AMPK and
mTOR, as well as the upstream PI3K/AKT proteins. We
found, as expected, that POLG-mutant astrocytes showed
suppressed AMPK and activated mTOR via upstream PI3K/AKT
proteins. Similar to our findings, studies have demonstrated
that autophagy in PD dopaminergic cells was regulated
by the AMPK/mTOR signaling pathway, suggesting that
AMPK/mTOR-mediated autophagy may also be a potential
therapeutic target for the treatment of PD patients (Ng et al.,
2012). Together, our findings support the suggestion that
changes in the AMPK/mTOR signaling pathway contribute to
the POLG-induced mitophagy dysfunction.
Previously, we reported that POLG-mutant astrocytes
exhibited abnormal NAD+ metabolism via SIRT1-dependent
regulation (Liang et al., 2020a). SIRT1 is a highly conserved
NAD+-dependent protein deacetylase that has emerged as a
critical mitophagy regulator (Fang et al., 2014). SIRT1 is also
required for AMPK activation (Price et al., 2012) and can
induce mitophagy activity via regulating AMPK/mTOR/ULK
signaling (Mei et al., 2020). Recent work has suggested
that supplementation with the NAD+ precursor NR can
potentially restore NAD+ metabolic profiles and improve
mitophagy in a ULK1-dependent manner (Fang et al.,
2019a). We therefore treated our patient astrocytes with
NR to increase SIRT1 activity and investigated the effects on
AMPK/mTOR-dependent mitophagy. Despite finding that
SIRT1 phosphorylation was increased, NR treatment alone failed
to alter AMPK/mTOR-related proteins or rectify the mitophagy
defects in POLG-mutant astrocytes.
Studies have also suggested that metformin might be beneficial
by maintaining SIRT1 activity during the aging process when
NAD+ levels decline (Bhansali et al., 2020). Moreover, previous
studies showed that metformin upregulated mitophagy markers
and enhanced mitophagic flux through the AMPK pathway
(Bhansali et al., 2020). Our studies showed that metformin
activated AMPK and mTOR, but did not increase SIRT1 activity.
Metformin stimulated mitophagy in POLG-mutant astrocytes as
evidenced by increased LC3B conversion and p62 expression.
Thus, given that metformin and NR appeared to activate
different parts of the mitophagy process, we asked whether dual
treatment would ameliorate the mitophagy defects in POLG-
mutant astrocytes. Our results suggest that this is the case: not
only does dual treatment significantly elevate LC3B-II/LC3B-I
ratio and p62 level, but it also improves mitophagy and lysosome
formation in POLG-mutant astrocytes.
Metformin is known to inhibit complex I, but this
is concentration dependent: at higher concentrations it
inhibits, while at lower concentrations it appears to improve
mitochondrial respiratory chain function (Wang et al., 2019). In
our study, we showed an increased complex I expression with NR
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and lower concentration metformin co-treatment. Mitochondrial
biogenesis and mitochondrial functional properties were also
increased in patient astrocytes following exposure to the co-
treatment. In an earlier study (Liang et al., 2020b), we showed
that POLG mutations lead to mtDNA depletion and loss of
complexes I and IV in astrocytes. These changes also led to ATP
depletion and abnormal NAD+ metabolism. Our current studies
demonstrate that POLG-mutant astrocytes also have impaired
mitophagy (Figure 8J). It is possible to hypothesize, therefore,
that the neuronal loss associated with POLG mutations might
occur via two mechanisms; first, loss of normal mitochondrial
function and disrupted mitophagy impairs normal astrocytic
support function, and second, the mitochondrial defects cause
astrocytes to become reactive and neurotoxic. Our work suggests
that treatment of NR and metformin potentially improves both
the mitochondrial functional deficit and mitophagy offering
a way of rescuing the disease phenotype in patients with
POLG mutations.
CONCLUSION
Overall, these results identify that POLG mutations lead to
accumulation of damaged mitochondria which can further
impart the mitophagy machinery by regulating the PINK1/Parkin
and AKT/mTOR/AMPK/ULK1 signaling pathway in astrocytes.
Further and most notably, we reveal that NR and metformin
rescued mitophagy defect in the POLG-mutant astrocytes,
providing new possibilities for the treatment of these disorders
by using mitophagy-enhancing reagents.
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